---
import BaseLayout from '../../layouts/BaseLayout.astro';
import MedicalDisclaimer from '../../components/MedicalDisclaimer.astro';

// Affiliate links
const affiliateLinks = {
  medvi: 'https://medvi.org/?page=multi&uid=5&oid=2&affid=2&pol=5&sub1=1350&sub1=1350&oid2=4412&affid2=1350',
  remedy: 'https://remedymeds.com/?rm_campaign=NY2026&toclid=TO-67s0pOKaInPCeJQvjBB7oL&utm_source=theoffer&utm_campaign=94',
  ro: 'https://track.revoffers.com/aff_c?offer_id=959&aff_id=9953&url_id=11818'
};
---

<BaseLayout 
  title="Retatrutide FDA Approval Timeline: When Will It Be Available? (2026-2028)"
  description="Track retatrutide's path to FDA approval. Phase 3 trial updates, submission timeline, and when you can expect to access Eli Lilly's triple agonist weight loss medication."
>
  <style>
    .hero {
      background: linear-gradient(135deg, #f59e0b 0%, #d97706 100%);
      color: white;
      padding: 80px 24px 60px;
      text-align: center;
    }
    
    .hero-badge {
      display: inline-block;
      background: rgba(255, 255, 255, 0.2);
      backdrop-filter: blur(10px);
      padding: 8px 20px;
      border-radius: 100px;
      font-size: 0.9rem;
      font-weight: 600;
      margin-bottom: 20px;
    }
    
    .hero h1 {
      font-size: clamp(2.2rem, 5vw, 3rem);
      font-weight: 700;
      margin-bottom: 16px;
      line-height: 1.2;
    }
    
    .hero p {
      font-size: 1.15rem;
      opacity: 0.95;
      max-width: 700px;
      margin: 0 auto;
    }
    
    .content {
      max-width: 900px;
      margin: 0 auto;
      padding: 60px 24px 120px;
    }
    
    .last-updated {
      background: #fef3c7;
      border-left: 4px solid #f59e0b;
      padding: 16px 20px;
      border-radius: var(--r);
      margin: 32px 0;
      font-size: 0.95rem;
    }
    
    .timeline {
      position: relative;
      padding-left: 40px;
      margin: 40px 0;
    }
    
    .timeline:before {
      content: '';
      position: absolute;
      left: 15px;
      top: 0;
      bottom: 0;
      width: 3px;
      background: var(--border);
    }
    
    .timeline-item {
      position: relative;
      margin-bottom: 40px;
    }
    
    .timeline-dot {
      position: absolute;
      left: -32px;
      top: 4px;
      width: 16px;
      height: 16px;
      border-radius: 50%;
      background: white;
      border: 3px solid var(--border);
    }
    
    .timeline-dot.completed {
      background: #10b981;
      border-color: #10b981;
    }
    
    .timeline-dot.current {
      background: #f59e0b;
      border-color: #f59e0b;
      box-shadow: 0 0 0 4px rgba(245, 158, 11, 0.2);
    }
    
    .timeline-date {
      font-size: 0.9rem;
      font-weight: 700;
      color: var(--text-sec);
      margin-bottom: 4px;
    }
    
    .timeline-title {
      font-size: 1.3rem;
      font-weight: 700;
      margin-bottom: 8px;
      color: var(--text-primary);
    }
    
    .timeline-desc {
      font-size: 1rem;
      line-height: 1.6;
      color: var(--text-sec);
    }
    
    .status-badge {
      display: inline-block;
      padding: 4px 12px;
      border-radius: 100px;
      font-size: 0.8rem;
      font-weight: 600;
      margin-left: 8px;
    }
    
    .status-completed {
      background: #d1fae5;
      color: #065f46;
    }
    
    .status-current {
      background: #fef3c7;
      color: #92400e;
    }
    
    .status-upcoming {
      background: #e0e7ff;
      color: #3730a3;
    }
    
    .content h2 {
      font-size: 2rem;
      font-weight: 700;
      margin: 48px 0 16px;
    }
    
    .content p {
      font-size: 1.05rem;
      line-height: 1.7;
      color: var(--text-sec);
      margin-bottom: 20px;
    }
    
    .content ul {
      margin: 20px 0;
      padding-left: 24px;
    }
    
    .content li {
      font-size: 1.05rem;
      line-height: 1.7;
      color: var(--text-sec);
      margin-bottom: 12px;
    }
    
    .trial-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
      gap: 20px;
      margin: 32px 0;
    }
    
    .trial-card {
      background: var(--surface);
      border: 1.5px solid var(--border);
      border-radius: var(--r);
      padding: 24px;
    }
    
    .trial-name {
      font-size: 1.2rem;
      font-weight: 700;
      margin-bottom: 12px;
      color: var(--text-primary);
    }
    
    .trial-meta {
      font-size: 0.9rem;
      color: var(--text-sec);
      margin-bottom: 16px;
    }
    
    .trial-meta strong {
      color: var(--text-primary);
    }
    
    .email-capture {
      background: linear-gradient(135deg, #10b981 0%, #059669 100%);
      color: white;
      border-radius: var(--r);
      padding: 40px 32px;
      text-align: center;
      margin: 48px 0;
    }
    
    .email-capture h3 {
      font-size: 1.8rem;
      font-weight: 700;
      margin-bottom: 12px;
    }
    
    .email-capture p {
      font-size: 1.05rem;
      opacity: 0.95;
      margin-bottom: 24px;
    }
    
    .email-form {
      display: flex;
      gap: 12px;
      max-width: 500px;
      margin: 0 auto;
      flex-wrap: wrap;
      justify-content: center;
    }
    
    .email-input {
      flex: 1;
      min-width: 250px;
      padding: 14px 20px;
      border-radius: var(--r);
      border: none;
      font-size: 1rem;
    }
    
    .email-submit {
      padding: 14px 32px;
      background: #1e293b;
      color: white;
      border: none;
      border-radius: var(--r);
      font-size: 1rem;
      font-weight: 600;
      cursor: pointer;
      transition: all 0.2s;
    }
    
    .email-submit:hover {
      background: #0f172a;
    }
  </style>

  <div class="hero">
    <div class="hero-badge">üìÖ Last Updated: February 2026</div>
    <h1>Retatrutide FDA Approval Timeline & Updates</h1>
    <p>
      Track the path to FDA approval for Eli Lilly's triple agonist weight loss medication showing 24-28.7% weight loss in clinical trials.
    </p>
  </div>

  <div class="content">
    <div class="last-updated">
      <strong>Last Updated: February 13, 2026</strong><br/>
      Latest: Eli Lilly announced 7 Phase 3 readouts expected throughout 2026. FDA submission anticipated by late 2026/early 2027.
    </div>

    <h2>The Timeline: When Will Retatrutide Be Available?</h2>

    <div class="timeline">
      <div class="timeline-item">
        <div class="timeline-dot completed"></div>
        <div class="timeline-date">June 2023 <span class="status-badge status-completed">‚úì Completed</span></div>
        <div class="timeline-title">Phase 2 Trial Results Published</div>
        <div class="timeline-desc">
          Published in <em>New England Journal of Medicine</em>. Results showed 24.2% average weight loss (12mg weekly dose) over 48 weeks. Established retatrutide as the most effective weight loss medication tested to date.
        </div>
      </div>

      <div class="timeline-item">
        <div class="timeline-dot completed"></div>
        <div class="timeline-date">December 2025 <span class="status-badge status-completed">‚úì Completed</span></div>
        <div class="timeline-title">First Phase 3 Trial Results (TRIUMPH-1)</div>
        <div class="timeline-desc">
          Eli Lilly announced retatrutide delivered up to <strong>28.7% average weight loss</strong> (71.2 lbs) in people with obesity and knee osteoarthritis. Results exceeded Phase 2 data, confirming retatrutide's superiority over existing medications.
        </div>
      </div>

      <div class="timeline-item">
        <div class="timeline-dot current"></div>
        <div class="timeline-date">Throughout 2026 <span class="status-badge status-current">‚óè In Progress</span></div>
        <div class="timeline-title">Seven Additional Phase 3 Readouts</div>
        <div class="timeline-desc">
          Eli Lilly has confirmed 7 more Phase 3 trials (TRIUMPH program) will report results in 2026. These trials test retatrutide in different populations: general obesity, diabetes + obesity, cardiovascular risk, liver disease, and more.
        </div>
      </div>

      <div class="timeline-item">
        <div class="timeline-dot"></div>
        <div class="timeline-date">Late 2026 / Early 2027 <span class="status-badge status-upcoming">Projected</span></div>
        <div class="timeline-title">FDA Submission (New Drug Application)</div>
        <div class="timeline-desc">
          After all Phase 3 data is collected and analyzed, Eli Lilly will submit a New Drug Application (NDA) to the FDA. Typical timeline: 3-6 months after final trial results.
        </div>
      </div>

      <div class="timeline-item">
        <div class="timeline-dot"></div>
        <div class="timeline-date">2027-2028 <span class="status-badge status-upcoming">Projected</span></div>
        <div class="timeline-title">FDA Approval Decision</div>
        <div class="timeline-desc">
          FDA standard review takes 10 months. Priority review (possible given obesity crisis) takes 6 months. <strong>Best case: Late 2027. Most likely: Q1-Q2 2028.</strong>
        </div>
      </div>

      <div class="timeline-item">
        <div class="timeline-dot"></div>
        <div class="timeline-date">2028 <span class="status-badge status-upcoming">Projected</span></div>
        <div class="timeline-title">Commercial Availability</div>
        <div class="timeline-desc">
          Retatrutide becomes available through pharmacies, telemedicine providers, and healthcare systems. Launch timeline: 1-3 months post-approval for initial rollout.
        </div>
      </div>
    </div>

    <h2>Phase 3 Clinical Trials: The TRIUMPH Program</h2>
    <p>
      Eli Lilly's Phase 3 program for retatrutide is called <strong>TRIUMPH</strong> (Triple Hormone Receptor Agonist in Patients with Obesity). Here's what we know:
    </p>

    <div class="trial-grid">
      <div class="trial-card">
        <div class="trial-name">TRIUMPH-1</div>
        <div class="trial-meta">
          <strong>Status:</strong> ‚úÖ Completed (Dec 2025)<br/>
          <strong>Population:</strong> Obesity + knee osteoarthritis<br/>
          <strong>Results:</strong> 28.7% weight loss (max dose)
        </div>
        <p style="font-size: 0.95rem; color: var(--text-sec); line-height: 1.6;">
          First Phase 3 to report. Showed retatrutide's efficacy and safety in people with obesity and joint pain. Bonus: significant reduction in osteoarthritis symptoms.
        </p>
      </div>

      <div class="trial-card">
        <div class="trial-name">TRIUMPH-2</div>
        <div class="trial-meta">
          <strong>Status:</strong> ‚è≥ Expected 2026<br/>
          <strong>Population:</strong> General obesity (no comorbidities)<br/>
          <strong>Estimated:</strong> 2,300 participants
        </div>
        <p style="font-size: 0.95rem; color: var(--text-sec); line-height: 1.6;">
          Testing retatrutide in people with obesity but no major health conditions. This will be the "core" weight loss trial for FDA approval.
        </p>
      </div>

      <div class="trial-card">
        <div class="trial-name">TRIUMPH-3 & Beyond</div>
        <div class="trial-meta">
          <strong>Status:</strong> ‚è≥ Expected 2026<br/>
          <strong>Populations:</strong> Diabetes, cardiovascular, liver disease<br/>
          <strong>Total:</strong> 6 more trials reporting
        </div>
        <p style="font-size: 0.95rem; color: var(--text-sec); line-height: 1.6;">
          Additional trials test retatrutide in people with type 2 diabetes, heart disease risk, fatty liver disease, and other obesity-related conditions.
        </p>
      </div>
    </div>

    <h2>What Could Delay or Accelerate Approval?</h2>

    <h3>Factors That Could Speed Up Approval</h3>
    <ul>
      <li><strong>Priority Review:</strong> FDA can grant 6-month review (vs 10-month standard) for significant advancements. Retatrutide's superior efficacy may qualify.</li>
      <li><strong>Clean Safety Data:</strong> If Phase 3 shows minimal serious adverse events, FDA may fast-track.</li>
      <li><strong>Obesity Crisis:</strong> Political/public health pressure to approve effective obesity medications quickly.</li>
      <li><strong>Early FDA Engagement:</strong> Eli Lilly likely discussing retatrutide with FDA throughout trials, reducing surprises.</li>
    </ul>

    <h3>Factors That Could Delay Approval</h3>
    <ul>
      <li><strong>Safety Signals:</strong> If rare serious side effects emerge in Phase 3, FDA will request more data.</li>
      <li><strong>Manufacturing Issues:</strong> Drug shortages (like tirzepatide/semaglutide) could delay launch even after approval.</li>
      <li><strong>Additional Studies Requested:</strong> FDA may want longer-term safety data or specific sub-population studies.</li>
      <li><strong>Regulatory Backlog:</strong> FDA review times can vary based on workload.</li>
    </ul>

    <h2>Will There Be a Clinical Trial I Can Join?</h2>
    <p>
      <strong>Possibly, but trials are filling fast.</strong> Search <a href="https://clinicaltrials.gov/search?term=retatrutide" target="_blank" rel="noopener" style="color: var(--primary); text-decoration: underline;">ClinicalTrials.gov for "retatrutide"</a> to find open trials.
    </p>
    <p>
      <strong>Typical eligibility criteria:</strong>
    </p>
    <ul>
      <li>BMI ‚â•30 (or ‚â•27 with weight-related health condition)</li>
      <li>Age 18-75</li>
      <li>No current use of other weight loss medications</li>
      <li>No history of pancreatitis, thyroid cancer, or certain GI disorders</li>
    </ul>
    <p>
      <strong>Benefits of trial participation:</strong> Free medication, close medical monitoring, contribution to science. <strong>Downside:</strong> You may be randomized to placebo (though crossover is common).
    </p>

    <h2>What to Do While Waiting for Retatrutide</h2>
    <p>
      <strong>Don't wait 1-2 years to start your weight loss journey.</strong> Here's what you should do now:
    </p>
    <ol>
      <li>
        <strong>Start tirzepatide (available now):</strong> Delivers 15-22.5% weight loss‚Äîexcellent results while you wait for retatrutide. You can switch later if you want even more weight loss.
      </li>
      <li>
        <strong>Sign up for retatrutide updates:</strong> Get notified the moment FDA approves and providers start offering it.
      </li>
      <li>
        <strong>Build healthy habits now:</strong> Combining medication with diet/exercise improvements maximizes results.
      </li>
    </ol>

    <div class="email-capture">
      <h3>üìß Get Notified When Retatrutide Is FDA Approved</h3>
      <p>Join the waitlist. We'll email you the day retatrutide becomes available through telemedicine providers.</p>
      <form class="email-form" action="https://compareweightmeds.us12.list-manage.com/subscribe/post" method="POST">
        <input type="hidden" name="u" value="YOUR_MAILCHIMP_U_ID">
        <input type="hidden" name="id" value="YOUR_MAILCHIMP_LIST_ID">
        <input 
          type="email" 
          name="EMAIL" 
          class="email-input" 
          placeholder="Enter your email" 
          required
        />
        <button type="submit" class="email-submit">Notify Me</button>
      </form>
    </div>

    <h2>Projected Market Impact</h2>
    <p>
      Industry analysts predict retatrutide will be a <strong>blockbuster drug</strong> with massive commercial impact:
    </p>
    <ul>
      <li><strong>Projected sales:</strong> $15.6 billion by 2031 (GlobalData estimate)</li>
      <li><strong>Market share:</strong> Expected to capture 30-40% of the GLP-1 weight loss market</li>
      <li><strong>Impact on competitors:</strong> Tirzepatide and semaglutide sales may plateau as patients switch to retatrutide</li>
      <li><strong>Pricing:</strong> Expect $900-1,400/month initially (matching current GLP-1 pricing)</li>
    </ul>

    <h2>The Bottom Line</h2>
    <p>
      <strong>Best Case Scenario:</strong> FDA approval by late 2027, availability by early 2028
    </p>
    <p>
      <strong>Most Likely Scenario:</strong> FDA approval by Q1-Q2 2028, availability by mid-late 2028
    </p>
    <p>
      <strong>What You Should Do:</strong> Start tirzepatide NOW ($179-499/month through telemedicine), then switch to retatrutide when it's approved if you want even better results.
    </p>

    <p style="margin-top: 48px;">
      <strong>Related Reading:</strong>
    </p>
    <ul>
      <li><a href="/peptides/retatrutide" style="color: var(--primary);">What Is Retatrutide? Complete Guide to the Triple Agonist Peptide</a></li>
      <li><a href="/peptides/retatrutide-vs-tirzepatide" style="color: var(--primary);">Retatrutide vs Tirzepatide: Which Is Better for Weight Loss?</a></li>
      <li><a href="/guides/tirzepatide-no-insurance" style="color: var(--primary);">How to Get Tirzepatide Without Insurance (2026)</a></li>
    </ul>

    <MedicalDisclaimer />
  </div>

  <!-- Sticky CTA Bar -->
  <div style="position: fixed; bottom: 0; left: 0; right: 0; background: linear-gradient(135deg, #10b981 0%, #059669 100%); padding: 16px 24px; text-align: center; box-shadow: 0 -4px 12px rgba(0,0,0,0.1); z-index: 100;">
    <div style="max-width: 1200px; margin: 0 auto; display: flex; align-items: center; justify-content: space-between; flex-wrap: wrap; gap: 12px;">
      <div style="color: white; font-weight: 600; font-size: 1.05rem;">
        Don't wait for 2028. Start tirzepatide today for $179/month.
      </div>
      <a href={affiliateLinks.medvi} target="_blank" rel="noopener sponsored" style="background: white; color: #059669; padding: 12px 32px; border-radius: 8px; font-weight: 700; text-decoration: none; white-space: nowrap;">
        Start with MEDVi ‚Üí
      </a>
    </div>
  </div>
</BaseLayout>
